Tag: Pentavalent antimonial

Leishmaniasis is a tropical disease affecting hundreds of thousands of people annually worldwide, causing a wide range of clinical presentations. The drug Glucantime (meglumine antimoniate), a pentavalent antimonial, has been a cornerstone in treating this parasitic infection for decades.

Leishmaniasis affects millions worldwide, with approximately 700,000 to 1 million new cases annually. A primary historical and current treatment for this disease is sodium stibogluconate, which is a key component in the fight against this debilitating parasitic infection.

Used in medicine since the 1940s, sodium stibogluconate (SSG) is a pentavalent antimonial agent historically used as a primary treatment for leishmaniasis, a parasitic disease caused by sandfly bites. The medication, once available as Pentostam, now faces significant issues with global supply and parasitic resistance, leading to its limited and highly specialized use.